DFDaniel P. Fitzgerald

Daniel P. Fitzgerald

*This is an algorithmically generated author record based on publicly available information.

Daniel P. Fitzgerald has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies

    by Kushal Prajapati, Chuan Yan, Qiqi Yang, Steven Arbitman, Daniel P. Fitzgerald, Sasan Sharee, Jahangheer Shaik, Jason Bosiacki, Kayla Myers, Ana Paucarmayta, et al.

    Cancers exploit coinhibitory receptors on T cells to escape tumor immunity, and targeting such mechanisms has shown remarkable clinical benefit, but in a limited subset of patients. We hypothesized that cancer cells mimic noncanonical mechanisms of early development such as axon guidance pathways to evade T cell immunity. Using gain-of-function genetic screens, we profiled axon guidance proteins on human T cells and their cognate ligands and identified fibronectin leucine-rich transmembrane protein 3 (FLRT3) as a ligand that inhibits T cell activity. We demonstrated that FLRT3 inhibits T cells through UNC5B, an axon guidance receptor that is up-regulated on activated human T cells. FLRT3 expressed in human cancers favored tumor growth and inhibited CAR-T and BiTE + T cell killing and infiltration in humanized cancer models. An FLRT3 monoclonal antibody that blocked FLRT3-UNC5B interactions reversed these effects in an immune-dependent manner. This study supports the concept that axon guidance proteins mimic T cell checkpoints and can be targeted for cancer immunotherapy.